Collegium Pharmaceutical, Inc. (COLL)

Market Cap	546.70M
Revenue (ttm)	313.51M
Net Income (ttm)	-35.25M
Shares Out	34.13M
EPS (ttm)	1.11
PE Ratio	14.43
Forward PE	3.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	249,381
Open	15.95
Previous Close	15.84
Day's Range	15.84 - 16.66
52-Week Range	14.04 - 22.89
Beta	0.85
Analysts	Buy
Price Target	33.46 (+108.9%)
Earnings Date	Nov 2, 2022

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Colle...

• Industry: Pharmaceuticals
• IPO Date: May 7, 2015
• CEO: Joseph Ciaffoni
• Employees: 152
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL

Full Company Profile

Financial Performance

In 2021, COLL's revenue was $276.87 million, a decrease of -10.69% compared to the previous year's $310.02 million. Earnings were $71.52 million, an increase of 167.33%.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 33.46, which is an increase of 108.86% from the latest price.

Price Target

$33.46

(108.86% upside)

Analyst Consensus: Buy

Stock Forecasts